Literature DB >> 24889968

Elevated perioperative serum CA 19-9 levels are independent predictors of poor survival in patients with resectable cholangiocarcinoma.

Naru Kondo1, Yoshiaki Murakami, Kenichiro Uemura, Takeshi Sudo, Yasushi Hashimoto, Hayato Sasaki, Taijiro Sueda.   

Abstract

BACKGROUND AND OBJECTIVES: Identification of prognostic markers is important to establish a perioperative therapeutic strategy for resectable cholangiocarcinoma (CC). The aim of this study was to investigate whether perioperative serum carbohydrate antigen 19-9 (CA19-9) levels can predict survival of patients who underwent surgical resection for CC.
METHODS: The study included 106 patients who underwent surgical resection for CC. Serum CA19-9 levels were measured preoperatively after biliary drainage and postoperatively about 4 weeks after surgery. The association of clinicopathological factors (including perioperative serum CA19-9 levels) with overall survival (OS) was analyzed with univariate and multivariate analyses.
RESULTS: Differences in OS were significant between groups divided on the basis of two preoperative CA19-9 cutoff values (in U/ml) of 37 and 200 and three postoperative CA19-9 cutoff values (in U/ml) of 37, 100, and 200. In multivariate analysis, absence of postoperative adjuvant chemotherapy (P = 0.002), lymph node metastasis (P = 0.0002), preoperative CA19-9 (≥ 200 IU/ml) (P = 0.03), and postoperative CA19-9 (≥ 37 IU/ml) (P < 0.0001) were identified as independent predictors of poor OS.
CONCLUSION: Both pre- and postoperative serum CA19-9 levels predict the survival of patients with resectable CC, and may contribute to the establishment of a new therapeutic strategy.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  CA19-9; cholangiocarcinoma; predictive marker; surgical resection

Mesh:

Substances:

Year:  2014        PMID: 24889968     DOI: 10.1002/jso.23666

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  25 in total

1.  Does the elevation of serum carbohydrate antigen 19-9 level predict poor overall survival in patients with hepatocellular carcinoma?

Authors:  Yan-Yan Wang; Jian-Hong Zhong; Zhan Lu; Hong-Gui Qin; Le-Qun Li
Journal:  Tumour Biol       Date:  2015-10-30

2.  Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis.

Authors:  John R Bergquist; Tommy Ivanics; Curtis B Storlie; Ryan T Groeschl; May C Tee; Elizabeth B Habermann; Rory L Smoot; Michael L Kendrick; Michael B Farnell; Lewis R Roberts; Gregory J Gores; David M Nagorney; Mark J Truty
Journal:  J Surg Oncol       Date:  2016-07-20       Impact factor: 3.454

3.  Serum p53 antibody as a potential tumor marker in extrahepatic cholangiocarcinoma.

Authors:  Rei Okada; Hideaki Shimada; Yuichiro Otsuka; Masaru Tsuchiya; Jun Ishii; Toshio Katagiri; Tetsuya Maeda; Yoshihisa Kubota; Tetsuo Nemoto; Hironori Kaneko
Journal:  Surg Today       Date:  2017-05-15       Impact factor: 2.549

4.  Gallbladder Cancer Presenting with Jaundice: Uniformly Fatal or Still Potentially Curable?

Authors:  Thuy B Tran; Jeffrey A Norton; Cecilia G Ethun; Timothy M Pawlik; Stefan Buettner; Carl Schmidt; Eliza W Beal; William G Hawkins; Ryan C Fields; Bradley A Krasnick; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles R Scoggins; Perry Shen; Harveshp D Mogal; Kamran Idrees; Chelsea A Isom; Ioannis Hatzaras; Rivfka Shenoy; Shishir K Maithel; George A Poultsides
Journal:  J Gastrointest Surg       Date:  2017-05-11       Impact factor: 3.452

5.  Predictors of postoperative early recurrence of extrahepatic bile duct cancer.

Authors:  Masayuki Akita; Tetsuo Ajiki; Kimihiko Ueno; Daisuke Tsugawa; Yu Hashimoto; Motofumi Tanaka; Masahiro Kido; Hirochika Toyama; Takumi Fukumoto
Journal:  Surg Today       Date:  2019-09-23       Impact factor: 2.549

6.  Prognostic Impact of the Initial Postoperative CA19-9 Level in Patients with Extrahepatic Bile Duct Cancer.

Authors:  Yuichiro Kato; Shinichiro Takahashi; Naoto Gotohda; Masaru Konishi
Journal:  J Gastrointest Surg       Date:  2016-06-01       Impact factor: 3.452

7.  Surgical Indication for Advanced Intrahepatic Cholangiocarcinoma According to the Optimal Preoperative Carbohydrate Antigen 19-9 Cutoff Value.

Authors:  Yusuke Yamamoto; Teiichi Sugiura; Akiko Todaka; Yukiyasu Okamura; Takaaki Ito; Ryo Ashida; Yuko Kakuda; Yasuni Nakanuma; Katsuhiko Uesaka
Journal:  World J Surg       Date:  2018-10       Impact factor: 3.352

8.  [CA19-9 in intrahepatic cholangiocarcinoma : A diagnostic and prognostic armamentarium?]

Authors:  B Juntermanns; G M Kaiser; S Itani Gutierrez; M Heuer; M Buechter; A Kahraman; H Reis; S Kasper; A Paul; C D Fingas
Journal:  Chirurg       Date:  2018-06       Impact factor: 0.955

9.  A model for predicting post-liver transplantation recurrence in intrahepatic cholangiocarcinoma recipients.

Authors:  Ao Ren; Zhongqiu Li; Xuzhi Zhang; Ronghai Deng; Yi Ma
Journal:  J Gastrointest Oncol       Date:  2020-12

Review 10.  Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice?

Authors:  Alice Boilève; Marc Hilmi; Matthieu Delaye; Annemilaï Tijeras-Raballand; Cindy Neuzillet
Journal:  Cancers (Basel)       Date:  2021-05-30       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.